RiverFront Investment Group’s Gilead Sciences GILD Stock Holding History

RiverFront Investment Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$645K	Buy	5,103 +1,514	+42%	+$199K	0.01%	271
2026 Q1	$500K	Buy	3,589 +142	+4%	+$19.9K	0.01%	261
2025 Q4	$423K	Sell	3,447 -291	-8%	-$35.4K	0.01%	250
2025 Q3	$415K	Buy	+3,738	New	+$425K	0.01%	232
2025 Q2	–	Sell	-1,924	Closed	-$216K	–	320
2025 Q1	$216K	Buy	+1,924	New	+$199K	﹤0.01%	270
2021 Q3	–	Sell	-3,649	Closed	-$251K	–	106
2021 Q2	$251K	Buy	3,649 +138	+4%	+$9.21K	0.01%	123
2021 Q1	$227K	Buy	+3,511	New	+$226K	﹤0.01%	113

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RiverFront Investment Group's GILD Position: Q2 2026 in Review

RiverFront Investment Group increased its Gilead Sciences (GILD) stake by 42% in Q2 2026, buying an estimated $199K and bringing the position to 5,103 shares worth $645K. The position accounts for 0.01% of the portfolio, ranked #271.

RiverFront Investment Group first reported a position in GILD in Q1 2021 and has held it in 7 quarters since. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

RiverFront Investment Group held 5,103 shares of Gilead Sciences worth $645K as of Q2 2026.
RiverFront Investment Group bought 1,514 Gilead Sciences shares in Q2 2026, an estimated $199K.
Gilead Sciences made up 0.01% of RiverFront Investment Group's portfolio in Q2 2026, its #271 holding.
RiverFront Investment Group first reported a position in Gilead Sciences in Q1 2021 and has held it in 7 quarters since.
2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on RiverFront Investment Group's 13F filing for Q2 2026, filed 29 Jul 2026.